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Abstract 
PTEN is one of the most frequently mutated tumor suppressor genes in human 
cancers. Loss of function alteration of PTEN results in increased activation of PI3K/Akt 
signaling, which is associated with increased proliferation, survival and neoplastic 
growth. Here, we have addressed the effects of conditional deletion of PTEN in 
hematopoietic cells. For this purpose, we have crossed PTEN conditional knock-out 
mice with a knock-in mouse expressing the CRE recombinase in the CD45 locus 
(CD45:Cre; PTEN fl/fl). CD45 is also known as leucocyte common antigen and is 
expressed in virtually all white cells as well as in hematopoietic stem cells. Using a 
reporter mice, we demonstrate that CD45:Cre mouse displays recombinase activity in 
both myeloid and lymphoid cells. However, CD45:Cre+/- PTENfl/fl mice develop T-
Acute lymphoblastic Leukemia and Lymphoma, but no other types of hematological 
malignancies such as myeloproliferative disorders of B-cell lymphomas. These results 
indicate that conditional deletion of PTEN in hematopoietic CD45-positive cells diverts 
neoplastic growth to the formation of T-cell malignancies. 
 Introduction 
PTEN (phosphatase and tensin homolog deleted on chromosome 10) encodes a dual 
lipid and protein phosphatase that plays a crucial role in the phosphatidylinositol-3 
kinase/Akt/mammalian Target of Rapamycin (PI3K/Akt/mTOR) signaling pathway. 
PTEN dephosphorylates phosphatidylinositol-3,4,5-triphosphate (PIP3) to 
phosphatidylinositol-4,5-diphosphate (PIP2), thereby antagonizing the activation of the 
function of PI3K. 12( Loss of PTEN function causes the activation of PI3K/Akt signaling 
that leads to increased cell growth and survival.345  
PTEN is one of the most frequently mutated tumor suppressor genes in human 
cancers. The tumor suppressive function of PTEN was identified as the chromosome 
region 10q23 partially or completely deletd in multiple neoplasias. 67 Moreover, 
germline mutations of PTEN gene were identified in patiens with Cowden disease. 6 
Loss-of-function alterations of PTEN are frequently found in solid tumors such as 
glioblastomas, thyroid breast, colon prostate or endometrial carcinomas 8 and in 
hematological malignancies including both lymphoid 9101112 and myeloid neoplasms. 
131415  
The PI3K/AKT/mTOR pathway has been implicated in human leukemogenesis. The 
role of PTEN in maintenance of hematological homeostasis has been evidenced by 
PTEN knock-out (KO) mouse models. Mice hemizygous for PTEN (PTEN+/-) develop 
multiple neoplasias, including both solid and hematological malignancies. 161718 
Conditional deletion of both PTEN alleles in many cell types have been achieved by 
crossing conditonal PTEN floxed mice 19 with different Cre expression systems. We 
have recently demonstrated tamoxifen-inducible expression of Cre recombinase in 
epithelial cells leads to the development of thyroid, endometrial and prostate 
neoplasias. 20 Conditional PTEN deletion in hematological system also results in the 
appearance of malignancies. Tamoxifen-inducible Cre under the control of Rosa26 
promoter (R26CRE:ER) causes PTEN excision in a broad spectrum of cells, leading to 
development of multiple neoplasias including lymphomas. 21 Lck-mediated Cre 
expression allows conditional deletion of PTEN in double negative thymocytes, leading 
to development of T-cell lymphomas. 22 Finally, by using the polyinosine-polycytidine 
inducible Mx1-Cre mice (Yilmaz 2006) or the VE-cadherin-Cre mice, PTEN has been 
successfully deletes in hematopoietic stem cells (HSC). In both mice models, animals 
suffer from either acute myeloid leukemia (AML) or T-acute lymphoblastic 
leumekina/lymphoma (T-ALL). 
To date, there is no existing mouse model to achieve specific PTEN deletion in 
hematopoietic cells without affection of other cell types. In the present work, we have 
addressed the effects of conditional deletion of PTEN in CD45 expressing cells. For 
these purpose, we have crossed PTEN conditional knock-out mice with a knock-in 
mouse expressing the CRE recombinase in the CD45 locus. The resulting mouse 
develops T-ALL, but no other types of hematological malignancies. 
Materials and methods 
Ethical statement 
All procedures performed in this study followed the National Institute of Health Guide 
for the Care and Use of Laboratory Animals and were approved by the Committee on 
Ethics of Animal Experiments of Universitat de Lleida/IRB Lleida (CEEA). 
Mice 
Mice were housed and maintained in a barrier facility, and pathogen-free procedures 
were used in all mouse rooms. Up to 15 mice were housed together in each cage and 
kept in a 12-hour light/dark cycle at 22°C with ad libitum access to autoclaved food and 
water.  
Floxed homozygous PTEN (C;129S4-Ptentm1Hwu/J, hereafter called PTEN fl/fl) and 
reporter mT/mG (B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J) mice 
were obtained from the Jackson Laboratory  (Bar Harbor, ME, USA). CD45:Cre mice 
were kindly donated by Dr. Alexander Medvinsky. 23 
CD45:Cre PTEN fl/fl mice were bred in a mixed background (C57BL6; 129S4) by 
crossing PTEN fl/fl and CD45:Cre mice; this followed by backcrossing CD45:Cre+/- 
PTEN fl/+ and PTEN fl/fl mice. Three weeks after birth, animals were weaned and tails 
were cut in order to genotype them. Isolation and PCR analysis of tail genomic DNA 
was perfomed as previously described. 1924 
During all the study, humane endpoints were used. Mice were monitorized every day 
and euthanized when they showed lethargy, ruffled fur, haunched posture or anorexia. 
For this purpose, animals were anesthesized with isofluorane and sacrificed by cervival 
dislocation. Organs were collected and further processed for the different studies 
described below. 
Genotyping of PTEN deletion 
Genomic DNA was isolated from WT and KO spleens by standar procedures. Briefly, 
tissue was chopped and digested with 1mg/mL of proteinase K (Sigma, Sant Louis, 
MO) at 55ºC for 4 hours. Samples were boiled 5 minutes and DNA was precipitated 
with 100% ethanol. Standar PCR was performed using three different primers: 
common forward P1 5’-ACTCAAGGCAGGGATGAGC-3’, reverse P2 5’-
AATCTAGGGCCTCTTGTGCC-3’ and reverse P3 5’-
GCTTGATATCGAATTCCTGCAGC-3’. PCR products were resolved in agarose gels 
and visualized by ethidium bromide staining.  
Western blot analysis 
Spleens were washed with PBS, frozen in liquid nitrogen and homogenized in ice with 
lysis buffer (2% sodium dodecyl sulfate, 125 mmol/L Tris-HCl, pH 6.8). Samples were 
boiled for 5 minutes at 95ºC, sonicated for 30 seconds and centrifuged (10 minutes at 
15000 rpm). Supernatants were recovered and protein concentrations were determined 
with a protein assay kit (Bio-Rad, Hercules, CA). Equal amounts of proteins were 
subjected to SDS-PAGE and transferred to PVDF membranes (Millipore). Nonspecific 
binding was blocked by incubation with TBST (20 mmol/L Tris-HCl, pH 7.4, 150 mmol/L 
NaCl, 0.1% Tween-20) plus 5% of non-fat milk. Membranes were incubated with 
primary antibodies overnight at 4°C followed by 1hour incubation with secondary 
antibody diluted 1/10000 in TBST. Signal was detected with ECL Advance (Amersham 
Pharmacia, Buckinghamshire, UK). Anti phospho-AKT and anti-PTEN rabbit antibodies 
were purchased from Cell Signaling (Beverly, MA); polyclonal rabbit anti-Cre was from 
Novagen (Billerica, MA); monoclonal mouse anti cyclin D1 and anti c-Myc were from 
Santa Cruz Biotechnology (Santa Cruz, Ca); monoclonal mouse anti-tubulin was from 
Sigma Aldrich (St Louis, MO).   
Histopathology and Immunohistochemical analysis 
Animals were euthanized and organs were collected, formaline-fixed O/N at 4ºC 
embedded in paraffin for histologic examination. Paraffin blocks were sectioned at a 
thickness of 3 μm, dried for 1h at 65º before pre-treatment procedure of 
deparaffinization, rehydration and epitope retrieval in the Pre-Treatment Module, PT-
LINK (DAKO) at 95 °C for 20 min in 50x Tris/EDTA buffer, pH 9. Before staining the 
sections, endogenous peroxidase was blocked. The antibodies used were against 
CD3ε (clone M-20, Santa Cruz Biotechnology), PTEN (clone 6H2.1), Ki67 (clone TEC-
3, DAKO, Denmark), CD20 (clone L26, DAKO, Denmark) and Myeloperoxidase 
(polyclonal, DAKO, Denmark). After incubation, the reaction was visualized with the 
EnVision FLEX Detection Kit (DAKO, Denmark) for CD20, C-KIT, Myeloperoxidase and 
PTEN, Polyclonal Rabbit Anti-Rat Immunoglobulins/Biotinylated and Streptavidin 
(DAKO, Denmark) for ki67 and Polyclonal Bovine Anti-Goat IgG/Biotinylated (Santa 
Cruz Biotechnology) and Streptavidin (DAKO, Denmark) for CD3ε using 
diaminobenzidine chromogen as a substrate. Sections were counterstained with 
hematoxylin. Appropriate negative controls were also tested. Representative images 
were taken with a Leica DMD 108 microscope. 
Hematoxilyn and Eosin (H&E) stained samples were histologically reviewed and 
evaluated by two pathologists, following uniform pre-established criteria 
Cytological analysis 
Blood was collected from the submandibular vein and smears were immediately 
prepared and fixed in 100% ethanol. For diff-quick staining, slides were fixed with Diff-
Quick fixative reagent and stained with Diff-Quick solution I (eosinophilic) and Diff-
Quick solution II (basophilic) before being brought to destilled water, air dried and 
mounted. 
For Papanicolau stain, ethanol fixed slides were stained with hematoxylin and 
counterstained with Orange G and Eosin Azure (EA50), cleaned with 95% ethanol and 
mounted. 
Proliferation analysis  
50 high power microscope fields were examined for mitotic figures and counted. 
Ki-67 staining was used to asses the index of proliferation of splenic cells in KO and 
WT mice. Five representative fields of each tissue were photographed for each animal.  
Proliferation was calculated as the percentage of Ki-67 positive nuclei to the total 
number of nuclei of each field (1000-2000 total nuclei were evaluated for each animal). 
Counting was performed using ImageJ software (WayneRasband, NIH, Bethesda, MD). 
FACS 
Blood was collected from the submandibular vein in heparinized capillars. Bone 
marrow cells were obtained from the long bones (tibias and femurs). After cleaning 
them from adherent soft tissue, the tip of each bone was removed and the marrow was 
harvested by inserting a syringe needle (30-gauge) into the end of the bone and 
flushing Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco). Spleen was chopped 
and digested 30 minutes at 37ºC in DMEM with 1mg/mL of collagenase D  (Sigma, 
Sant Louis, MO). Splenocytes were filtered through a 70 μm-strainer (MARCA) and 
centrifuged. Red blood cells were removed from blood, bone marrow and spleen 
samples using lysis buffer (0, 15M NH4Cl, 0,01M KHCO3, 0,1 EDTA) FACS analysis of 
the bright cells was performed using the following antibodies: APC anti-mouse TCR 
and FITC anti-mouse B220, both obtained from EBioscience.   
For the reporter CD45:Cre mT/mG mice analysis, blood and BM were collected as 
described and green/red fluorescences were analysed. 
Fluorescence emission was measured using FACSCalibur (BD Biosciences, San Jose, 
CA, USA) 
CD45:Cre reporter assays 
For reporter assays of the cre activity, CD45:Cre+/- and mT/mG+/+ mice were bred. 
The resulting offspring was weaned and genotyped. One month after birth, CreER+/- 
mT/mG+/- mice were sacrified and organs were collected and fixed in 4% PFA for 4 
hours at room temperature. Samples were cryoprotected in PBS with 30% sucrose 
overnight at 4ºC and embedded in OCT (VWR International). 8-μm sections of frozen 
tissue were cut with cryostat and nuclei were counterstained with Hoescht and samples 
mounted with PBS:glycerol (1:1). 
Tissue immunofluorescence was visualized and analyzed using a confocal microscope 
(Olympus, Tokyo, Japan). Confocal images were edited using FluoView software 
(Olympus). 
Statistical analysis 
Experiments were performed at least three times and statistical significance was 




Generation of conditional mouse model to delete PTEN in CD45-expressing cells 
 
To achieve conditional deletion of the two PTEN alleles in CD45 expressing cells, 
conditional PTEN knock-out mouse (PTENfl/fl) 19 was crossed with a knock-in mouse 
expressing Cre recombinase into the CD45 locus (CD45:Cre) 23 
 
We fist evaluated the effects of conditional deletion of the two PTEN alleles in mice 
lifespan (Fig.1A). Kaplan-Meier analysis of mice survival revealed that none of the mice 
(female n=15; male n=5) expressing Cre recombinase and the two floxed PTEN alleles 
(CD45:Cre+/- PTEN fl/fl, designed as KO) survived beyond 30 weeks of age. Mice 
lacking Cre expression but having two PTEN floxed alleles (CD45-/- PTEN fl/fl 
designed as wild type, WT) showed normal survival (females n=15; males n=4). 
 
Necropsy of CD45:Cre+/- PTEN fl/fl mice revealed that 100% of male and female mice 
had severe splenomegaly, hepatomegaly and enlargement of other lymphoid organs 
such as the thymus and the lymph nodes (Fig. 1B). To demonstrate Cre mediated 
recombination of PTEN in lymphoid organs, we performed genotyping and western blot 
analysis of the spleen from one WT mouse and two KO littermates (Fig 1C). 
Genotyping demonstrated the presence of an amplified band corresponding to the 
recombined allele in KO mice. Accordingly, western blot analysis confirmed complete 
loss of PTEN expression and increased Akt phosphorylation in KO mice (Fig 1D). 
 
Deletion of PTEN in CD45.expressing cells leads to development of diffuse 
peripheral lymphomas/leukemias 
 
As mentioned above, macroscopic evaluation evidenced a marked increase of 
lymphoid organs, thus suggesting that conditional deletion of PTEN in CD45 cells leads 
to development to lymphomas. To further demonstrate the presence of such 
malignancies, we performed histopathologic analysis of both lymphoid and non-
lymphoid tissues. Histopathological examination of the spleen revealed loss of PTEN 
expression with a disruption of its normal architecture by a diffuse infiltration of 
lymphoid cells (Fig. 2A) that exhibited irregular nuclei, prominent nucleoli and high 
mitotic rates (Fig. 2B) as well as cytologic atypia and strong Ki-67 immunoreactivity 
(Fig. 2C). Western blot analysis revealed a marked increase of cyclin D1 and c-Myc 
expression in KO mice spleens (Fig. 2D), both of them targets of PTEN in 
lymphomagenesis.  
 
Histopathological analysis of other organs demonstrated atypical lymphoid cells lacking 
PTEN infiltrating in kidneys, live, lungs, colon or ovary (Fig. 3A). Moreover, flow 
cytometer analysis and peripheral blood extension from WT and KO mice revealed a 
dramatic increase of lymphocyte population (Fig 3B, 3C). These results suggest that 
deletion of PTEN in CD45 expressing cells results in development of severe 
leukemia/lymphomas.  
 
CD45:Cre+/- PTENfl/fl mice develp T-cell but not B-cell lymphomas 
 
Next, we investigated the nature of lymphomas observed in CD45:Cre+/- PTENfl/fl 
mice. For this purpose, we performed flow cytometry analysis using B220 and anti-TCR 
antibodies to differentiate B-lymphocytes from T-lymphocytes. Analysis of bone 
marrow, blood and spleen samples obtained from WT and KO mice revealed a marked 
decrease of B lymphocytes and an increased population of T-cells in KO mice (Fig 4A), 
suggesting that the malignancies developed by KO mice were compatible with T-cell 
lymphoma. To further demonstrate T-cell nature of lymphomas, we carried out 
immunohistochemical analysis of KO spleens, lymph nodes and bone marrow with 
anti-CD3 antibodies, which specifically recognize T cells. In WT mice, CD3+ cells 
location was restricted to paracortical zone of lymph nodes and the periarteriolar 
lymphoid sheath of the spleen (Fig 4B). In contrast in KO mice, bone marrow, as well 
as the germinal centers of both lymph nodes and spleens, were invaded by CD3+ cells. 
To address the presence of remaining myeloid cells in these tissues, we performed 
immunostaining of myeloperoxidase (MPO) in all of them. As expected, due to the 
increase in the lymphoid population, PTEN deletion caused a marked decrease of 
myeloperoxidase expressing cells. (Fig 4C)  
 
Accordingly to the described results, lymphocytic infiltrates found in liver, lung, kidney 
or colon, were positive for CD3 staining (Fig 4D). Immunohistochemistry analysis of 
blood extensions also revealed an increase of CD3 expressing cells in peripheral blood 
(Fig4D). These results indicate that in all cases analyzed, KO mice developed T-cell 
lymphoma/leukemia, with no myeloid or B cell disease. 
 
CD45:Cre mouse display recombinase activity in myeloid and lymphoid lineages 
 
CD45 is expressed in all nucleated hematopoietic cells, including both lymphoid and 
myeloid lineages. However, all CD45:Cre+/- PTEN fl/fl mice analyzed showed T-ALL 
while none of them seemed to develop myeloid malignancies. Thus, we wondered 
whether CD45:Cre recombinase activity was causing recombination (and therefore 
PTEN ablation) in both cell lineages. To test CD45:Cre recombinase activity, we 
crossed CD45:Cre mice with a double fluorescent reporter mouse that expresses  
membrane-targeted tandem dimer Tomato (mT) prior to Cre mediated excision, and 
membrane-targeted green fluorescent protein (mG) after excision (mT/mG mouse).24 
One month after birth, the resulting offspring (CD45:Cre+/- mT/mG+/-) was analyzed 
for the presence of red and green fluorescence by flow cytometry and confocal 
microscopy. First, we analyzed the percentage of myeloid cells and lymphocytes 
displaying red of green fluorescence in peripheral blood samples. Flow cytometric 
analysis revealed the presence of both lymphocytes and myeloid cells expressing 
green fluorescence (Fig 5A), suggesting that Cre activity was able to induce 
recombination in both cell populations. These results were further confirmed by 
confocal microscopy analysis of peripheral blood and bone marrow extensions, as well 
as spleen and lymph node sections. In all those tissues, we observed the presence of 
green lymphocytes and granulocytes (Fig 5B). The evidences indicate that, as 
expected, the expression and activity of Cre recombinase under the control of CD45 
promoter was able to cause recombination in all blood lineages, although the efficiency 
was higher in lymphoid cells than in myeloid populations. 
 
Discussion 
In the present report, we have investigated the effects of conditional deletion of PTEN 
in hematopoietic cells. To date, there is no existing mouse model to achieve deletion of 
PTEN exclusively in hematopoietic cells, but not in other cell types.  For this purpose, 
we have crossed a previously described knock-in mouse expressing Cre recombinase 
in CD45 locus23 with conditional PTEN floxed mouse. Such combination resulted in a 
mouse model that specifically deletes PTEN in hematopoietic system, but not in other 
cell type, resulting in the development of T-ALL but no other types of solid or 
hematological malignancies.  
CD45 encodes a receptor type protein with phosphatase activity that is expressed in all 
nucleated hematopoietic cells, including hematopoietic stem cells. and mature 
lymphoid and myeloid cells. For this reason, CD45 has traditionally been designated as 
the Leucocyte Common Antigen (LCA) and commonly used to distinguish 
hematopoietic cells by either flow cytometry or immunohistochemistry. Here, we have 
demonstrated that conditional deletion of PTEN in CD45 expressing cells leads to 
development of T-ALL, with no evidence of other hematological malignancies. These 
results raise several questions. First question is, why conditional PTEN deletion in all 
CD45 cells only develops lymphoid neoplasms but no other types of hematological 
manlignancies? Second, why all lymphoid neoplasms correspond to T-cell 
malignancies but none of the mice analyzed showed evidence of B-cell neoplasias? 
Regarding the first question, we considered the possibility that PTEN was not deleted 
in myeloid cells because Cre recombinase was not efficiently expressed in this lineage. 
However, using mT/mG reporter mice, we have demonstrated Cre recombination in 
both myeloid and lymphoid cells. Although these results suggest that loss of PTEN in 
hematopoietic cells favors the formation of lymphoid malignancies, we cannot rule out 
the possibility that the differences observed are affected by differences in the efficiency 
of recombination, which is lower in the myeloid lineage. Two previous studies have 
demonstrated that PTEN expression is required to maintain HSCs and participates in 
lineage choice and leukemogenesis. 2526. The use of Mx1-Cre mice for PTEN ablation 
leads to a rapid formation of myeloproliferative disease (MPD) that mainly progresses 
to acute myeloid leukemia (AML) 2526 On the other hand, the use of the VE-cadherin-
cre mice for PTEN excision has been reported to cause T-ALL in 74% of the animals 
analyzed. 27 It is important to note that in the first model, PTEN is silenced in adult mice, 
while in the second one it occurs at the fetal level. In this sense, our model is closer to 
the VE-cadherin-cre mice, as CD45 is expressed already in the fetal state of 
hematopoiesis and we observe T-ALL but not any myeloid leukemia. These facts 
suggest that the outcome of the mutation can be affected not only by the tissue where 
it happens, but also the moment when it occurs. Another point to take into account is 
the fact that neither Mx1-Cre nor VE-cadherin-cre mice delete PTEN exclusively in 
hematopoietic cells. We report the first study where PTEN has been knocked in all the 
hematopoietic system since its very beginning without affecting other cell types and 
avoiding stimulation of the system with inducers as IFN, which has been reported to 
modulate hematopoiesis. 28 
Regarding the second question, is worth to mention that the vast majority of lymphoid 
neoplasms are of B-cell origin (85-90%), with most of the remainder being T cell 
tumors. 29Nonetheless, immunostaining analysis of KO mice revealed that 100% of 
mice displayed T-ALL, but none of them had signs of B-ALL. Previous studies have 
demonstrated that, while conditional deletion of PTEN in mouse T cells results in lethal 
T cell lymphomas 22, animals lacking PTEN in B cells showed altered B lymphocyte 
differentiation, but no evidence of malignancy.30 Furthermore, reduction of B cells has 
also been found by Zhang and collaborators 26 after conditional deletion of PTEN in 
HSCs using the inducible Mx1-Cre mouse. In agreement to these mouse models for 
conditional deletion of PTEN, our model suggests that PTEN ablation diverts the 
formation of lymphoid malignancies to T lineages. Accordingly, PTEN +/- mice, with a 
single copy of PTEN in all the cell of the organisms, develop T-cell lymphomas, but no 
B cell neoplasias. 161718 
In summary, we describe a new mouse model in which PTEN has been specifically 
deleted in CD45 positive hematopoietic cells. Such deletion resulted in the 
development of T-ALL, but no other types of hematological malignancies such as AML 
of B-cell lymphomas, indicating that loss of PTEN in hematopoietic cells diverts the 
formation of hematological neoplasias to the formation of T cell malignancies. As PTEN 
is a frequently mutated gene in human blood malignancies, understand how it 
regulates hematopoiesis and the tumorigenic process in mouse models is a valuable 
tool that will help to improve the understanding of the human disease and the 
designing of new therapies. 
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Figure 1. CD45:Cre+/- PTEN fl/fl mice develop a lethal disease that affects 
lymphoid organs. 
 
(A) Kaplan-Meier curve of WT and KO males and females analyzed for 60 weeks. 
Note that survival decrease dramatically after 20 weeks and none of the KO 
animals survived longer than 30 weeks. 
(B) Comparison of representative spleen, liver, thymus and lymph nodes from WT 
and KO mice. 
(C) Genotyping analysis by standard PCR of the recombined (delta) allele in spleen 
from KO but not from WT mice.  
(D) Western blot from WT and KO mice showing cre recombinase expression, in 
concordance with complete PTEN deletion and increase of Akt phosphorylation. 
Membranes were reproved with tubulin to ensure protein loading. 
 
Figure 2. Histopathological analysis reveals that PTEN deletion in CD45 
expressing cells leads to development of lymphomas. 
 
A) Representative images showing H&E staining (top panels) and PTEN 
immunohistochemistry (bottom panels) of spleen from WT and KO mice.  
B) Quantification of mitotic activity in spleens from WT and KO mice. Results are 
expressed as number of mitotic figures observed per 50 high-power microscope 
fields. 
C) Representative images and quantification of Ki-67 immunostaining in WT (left) 
and KO (right) mice.  
D) PTEN deletion in spleen from KO mice increases expression of cyclin D1 and c-
Myc, as showed by western blot. Membranes were reproved with tubulin to 
ensure protein loading. 
 
 
Figure 3. PTEN deletion in CD45:Cre mice causes diffuse peripheral 
lymphomas/leukemia. 
A) Representative images showing H&E staining (top panels) and PTEN 
immunohistochemistry (bottom panels) from WT and KO mice. Note the 
presence of PTEN negative infiltrates in different organs including lung, liver, 
colon, kidney and ovary. 
B) Flow cytometry analysis of blood samples from WT and KO mice. KO shows 
and increased percentage of lymphocytes in total blood. 
C) Representative images of papanicolau stained blood extensions obtained from 
WT and KO mice.  
 
Figure 4. CD45:Cre+/- PTEN fl/fl mice develop T cell but not B cell lymphomas 
  
A) Flow cytometry analysis of blood, bone marrow and spleen from WT and KO 
mice. Deletion of PTEN in CD45 cells leads to a dramatic increase in the 
amount of T lymphocytes, with a decrease in B cell population. 
B) Representative images of CD3 immunohistochemistry from spleen, lymph 
nodes and bone marrow from WT and KO mice. 
C) Representative images of myeloperoxidase immunohistochemistry from spleen, 
lymph nodes and bone marrow from WT and KO mice. 
D) Representative images of CD3 immunohistochemistry in lung, liver, kidney and 
colon from CD45:Cre+/- PTEN fl/fl (KO) mice. 
E) Representative images showing CD3 immunostaing of blood extension 
obtained from WT and KO mice. 
 
Figure 5. CD45:Cre+/- mice show recombination in all blood cell lineages. 
 
A) Flow cytometry analysis of peripheric blood from CD45:Cre mT/mG mice shows 
green and red fluorescence in both lymphocytes and granulocytes from 
CD45:Cre+/- mT/mG +/- animals. 
B) Representative confocal images corresponding to blood, bone marrow, spleen 
and lymph nodes from CD45:Cre+/- mT/mG +/- mice showing recombination y 
all tissues. Note the presence of recombined (green) lymphocytes (white 
arrows) and granulocytes (yellow arrows). 
 
 
  
 





